Analysts Cut Cardlytics Price Target After Guidance, BofA Exit

Analysts have reset price targets for Cardlytics (CDLX) closer to the $1.00 to $1.25 range, with a fair value estimate near $1.04. These changes follow Q4 results, Q1 guidance, the exit of Bank of America (BAC), and the divestiture of Bridg. Some analysts describe the stock as firmly in "show me" territory, indicating the market needs to see tangible performance.

Rating Change

• Previous Price Target: Not specified.
• New Price Target: $1.00 - $1.25.
• Rating: No explicit change mentioned, but the reduction reflects a more cautious stance.

Analyst Rationale

Analysts believe that Q4 results, weak Q1 guidance, the BofA exit, and the Bridg divestiture have reset expectations at a lower level. They consider the stock to be in a "show me" phase, where the company must prove its ability to grow and become profitable.

Context

• Stock Performance: Cardlytics shares have declined sharply over the past year.
• Other Analyst Opinions: Consensus appears cautious, with multiple price target cuts.
• Key Events: The loss of Bank of America as a key partner and the Bridg divestiture have weakened growth prospects.

What to Conclude (Neutral)

The price target cuts reflect uncertainty about Cardlytics' ability to recover. Investors are advised to monitor the company's developments closely, especially new partnerships and improved guidance.